KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Income towards Parent Company: 2009-2025

Historic Income towards Parent Company for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Sep 2025 value amounting to $251.1 million.

  • Alnylam Pharmaceuticals' Income towards Parent Company rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Income towards Parent Company of $251.1 million as of Q3 2025, which was up 478.84% from -$66.3 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Income towards Parent Company high stood at $251.1 million for Q3 2025, and its period low was -$405.9 million during Q3 2022.
  • Moreover, its 3-year median value for Income towards Parent Company was -$66.3 million (2025), whereas its average is -$53.7 million.
  • The largest annual percentage gain for Alnylam Pharmaceuticals' Income towards Parent Company in the last 5 years was 325.05% (2025), contrasted with its biggest fall of 292.43% (2025).
  • Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Income towards Parent Company stood at -$258.5 million in 2021, then grew by 19.72% to -$207.5 million in 2022, then skyrocketed by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then skyrocketed by 325.05% to $251.1 million in 2025.
  • Its Income towards Parent Company was $251.1 million in Q3 2025, compared to -$66.3 million in Q2 2025 and -$57.5 million in Q1 2025.